Items where Author is "Kanavos, P."

Number of items: 7.
  • HPR253 Drug development and launch timeline analysis across 6 high-income countries:from pivotal trial to HTA. Zaitceva, V and Tan, I and Mills, M. and Kanavos, P.
  • HTA117 Sentiment analysis of clinical evaluations in HTA:evidence from Canada, England, Scotland, Sweden, France, and Germany. Eaves, K. and Lin, R. and Alani, A. H. and Mills, M. and Kanavos, P.
  • HTA18 First to launch, first to falter?:an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Civitelli, D. and Politopoulou, K. and Mills, Mackenzie and Kanavos, P.
  • HTA246 Improving access to innovative therapies for rare bleeding disorders:evidence from high income countries. Alani, A. H. and Eaves, K. and Mills, Mackenzie and Kanavos, P.
  • HTA354 Determinants of added benefit ratings in Germany:an econometric analysis of assessments from the Federal Joint Committee between 2012 and 2024. Tolkmitt, F. and Chavez, D. and Mills, M. and Kanavos, P.
  • HTA64 Leveraging machine learning for predicting health technology assessment outcomes. Lin, R. and Eaves, K. and Mills, M. and Kanavos, P.
  • PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process. Chavez, D. and Tolkmitt, F. and Mills, M. and Kanavos, P.